11 Most Profitable NASDAQ Stocks to Buy Now

8. Biogen Inc. (NASDAQ:BIIB)

TTM Net Income as of June 13: $1.48 billion

Forward P/E Ratio as of June 13: 13.07

Number of Hedge Fund Holders: 52

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting in Barcelona, Spain.

The study showed clinical improvements in disease activity for individuals with moderate-to-severe systemic lupus erythematosus/SLE when treated with DZP in addition to standard of care/SOC. Systemic Lupus Erythematosus (SLE) is a chronic, multifactorial autoimmune disease characterized by the activation of autoreactive immune cells, leading to manifestations across various organ systems. It affects an estimated 90% of women, with symptoms typically appearing between the ages of 15-55.

The primary endpoint, which was measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment/BICLA at Week 48, showed positive results. It’s important to note that the safety and efficacy of DZP in SLE are not yet established, and it is not approved by any regulatory authority worldwide for this indication. A second Phase 3 trial, PHOENYCS FLY, is currently underway to confirm the findings from PHOENYCS GO.

Biogen Inc. (NASDAQ:BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases internationally. UCB is a global biopharmaceutical company that discovers and develops innovative medicines and solutions for severe diseases of the immune system or the CNS.